Femasys (NASDAQ:FEMY) CEO Kathy Lee-Sepsick Acquires 15,625 Shares of Stock

Femasys Inc. (NASDAQ:FEMY) CEO Kathy Lee-Sepsick acquired 15,625 shares of Femasys stock in a transaction on Friday, August 7th. The shares were bought at an average price of $3.20 per share, with a total value of $50,000.00. Following the purchase, the chief executive officer directly owned 15,625 shares in the company, valued at approximately $50,000. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Femasys Stock Down 0.8%

Shares of FEMY opened at $2.35 on Wednesday. Femasys Inc. has a 52 week low of $2.29 and a 52 week high of $22.20. The company has a quick ratio of 1.98, a current ratio of 3.91 and a debt-to-equity ratio of 0.53. The company has a market capitalization of $7.10 million, a price-to-earnings ratio of -0.44 and a beta of -2.08. The stock’s 50-day moving average price is $3.87 and its 200-day moving average price is $7.49.

Hedge Funds Weigh In On Femasys

Large investors have recently bought and sold shares of the business. Kovack Advisors Inc. purchased a new position in Femasys during the fourth quarter worth approximately $27,000. HRT Financial LP acquired a new position in shares of Femasys during the 4th quarter worth approximately $30,000. Cetera Investment Advisers acquired a new position in shares of Femasys during the 4th quarter worth approximately $36,000. Osaic Holdings Inc. purchased a new position in shares of Femasys during the 2nd quarter valued at approximately $45,000. Finally, State Street Corp lifted its position in shares of Femasys by 43.5% during the 4th quarter. State Street Corp now owns 80,869 shares of the company’s stock valued at $47,000 after buying an additional 24,500 shares in the last quarter. Institutional investors and hedge funds own 65.27% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on FEMY shares. Weiss Ratings raised shares of Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. Wall Street Zen raised shares of Femasys to a “hold” rating in a report on Saturday, June 13th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $80.00.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.